NCT07120737View on ClinicalTrials.gov

Efficacy and Safety of Spectacle Lenses With H.A.L.T. MAX Technology on High Myopia Control in Children and Adolescents

NANot yet recruitingINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

December 1, 2028

Conditions
MyopiaHigh Myopia
Interventions
DEVICE

H.A.L.T. MAX spectacles

The Essilor® Stellest® 2.0 lens features a 2 times larger signal area, significantly enhancing the effect of slowing down myopia progression

Trial Locations (1)

200336

Shanghai Eye Disease Prevention and Treatment Center (SEDPTC), Shanghai

Sponsors

Collaborators (1)

Essilor International
All Listed Sponsors
collaborator

Essilor International

INDUSTRY

lead

Shanghai Eye Disease Prevention and Treatment Center

OTHER